TH101548B - Coenzyme Q10 (CoQ10) formulations for intravenous administration to patients, and the methods of using these formulations. - Google Patents

Abstract

DC60 (04/12/55) The information disclosed herein is a suitable formulation for the intravenous administration of certain hydrophobic active ingredients, such as coenzyme Q10. It also provides a similar preparation method and a similar cancer treatment method. The formulation consists of an aqueous solution; the hydrophobic active ingredient, dispersed to form colloidal nano-dispersion of particles; and at least one dispersion, stabilizing agent, and optonization reducer, which disperses the colloidal nano-dispersion of the active ingredient into nano-dispersion particles with an average size less than 200 nm. The method for preparing the formulation for intravenous administration includes the dispersion of the hydrophobic active ingredient by high-pressure homogenization (1), the addition of the hydrophobic active ingredient to a 65 °C water bath and mixing to form a hydrophobic/water mixture; (2) Addition of dispersion stabilizer to the hydrophobic/aqueous active ingredient mixture and mixing at 65°C to form a hydrophobic/aqueous/stabilizer active ingredient mixture; (3) Addition of optonization reducer to form a hydrophobic/aqueous/stabilizer/reducer active ingredient mixture; (4) Initial heating of the microfluidizer to 65°C; and (5) Mixing of the hydrophobic/aqueous/stabilizer/reducer active ingredient mixture in the microfluidizer at 65°C to produce hydrophobic colloidal nano-dispersion of active ingredients with an average particle size smaller than 200 nm. In addition, the information provided here is a method of treating cancer abnormalities by giving the formula described herein to patients to achieve treatment or prevention of cancer. The information disclosed herein is a suitable formulation for the intravenous administration of certain hydrophobic active ingredients, such as coenzyme Q10. Similar preparation methods and cancer treatment methods using similar methods are also provided. The formulation consists of an aqueous solution; the hydrophobic active ingredient, dispersed to form a colloidal nano-dispersion of particles; and at least one dispersion, stabilizing agent, and optonization reducer, which disperses the hydrophobic active ingredient into nano-dispersion particles with an average size less than 200 nm. The formulation preparation method for intravenous administration includes high-pressure hydrophobic dispersion of the active ingredient (1) adding the hydrophobic active ingredient to a 65°C water bath and mixing to form a hydrophobic/aqueous mixture; (2) adding the dispersion, stabilizing agent to the mixture; (3) Addition of an optonization reducer to form a hydrophobic/water/stabilizer/reducer active ingredient mixture; (4) Initial heating of the microfluidizer to 65°C; and (5) Mixing of the hydrophobic/water/stabilizer/reducer active ingredient mixture in the microfluidizer at 65°C to produce a colloidal nano-dispersion of hydrophobic active ingredients with an average particle size smaller than 200 nm. In addition, the information provided here is a method of treating cancer abnormalities by giving the formula described here to patients to achieve treatment or prevention of cancer.

Claims (1)

1. An appropriate therapeutic regimen for intravenous administration should consist of: an aqueous solution; a hydrophobic active ingredient dispersed to form colloidal nano-dispersion of particles; and at least one dispersion stabilizing agent and opsonization reducer; which disperses the colloidal nano-dispersion of the active ingredient into nano-dispersion particles with an average size smaller than 200 nanometers.